Daiichi Sankyo Europe GmbH

Featured Stories

For the last ten years we as Daiichi Sankyo Europe have supported young graduates from the Ludwig-Maximilians-University in Munich (LMU). read more...

The new Daiichi Sankyo Group’s Value Report is now available! The report includes business facts & figures, information about Daiichi Sankyo’s growth potential, CSR activities and much more. read more...

Featured News

Date	Description
19/03/2019 Research	Daiichi Sankyo Presents Real-World Data from EMIT-AF/VTE That Demonstrates Peri-procedure use of Oral, Once-Daily LIXIANA®▼ (edoxaban) was Efficacious and Bleeding Incidence was Low, in Elderly European Non-Valvular Atrial Fibrillation, and Venous Thro	PDF
19/03/2019 Research	CLEAR Wisdom Demonstrated First-in-Class, Oral, Once-daily, ACL inhibitor Bempedoic Acid Significantly Lowered LDL-Cholesterol and Reduced hsCRP	PDF
18/03/2019 Products	Daiichi Sankyo Presents Positive Results of the First Randomised, Controlled Trial of Uninterrupted Oral, Once-daily LIXIANA®▼ (edoxaban) in Atrial Fibrillation Patients Undergoing Catheter Ablation	PDF
14/03/2019 Products	Bempedoic Acid Study 1 Results Published in The New England Journal of Medicine Demonstrates Significant LDL-Cholesterol Lowering and Reduced Marker of Underlying Cardiovascular Inflammation, with a Similar Tolerability to Placebo	PDF
13/03/2019 Products	Daiichi Sankyo Announces New Data on Once-Daily LIXIANA®▼ (edoxaban) to be Presented in Late-Breaking Sessions at EHRA 2019, the Annual Congress of the European Heart Rhythm Association	PDF
show all

Dear User, This website provides you with information only for healthcare professionals. According to the drug promotion code, we are only able to allow healthcare professionals like physicians and pharmacists to have full access to our website. To visit our page please login.

Daiichi Sankyo
Doc Check

Support For Young Talents

Value Report 2018